BiotechTubeBiotechTube
Home/Pipeline/Rozanolixizumab

Rozanolixizumab

Myasthenia Gravis

Phase 3Active

Key Facts

Indication
Myasthenia Gravis
Phase
Phase 3
Status
Active
Company
UCB

About UCB

UCB S.A. is a multinational biopharmaceutical company founded in 1928, originally as Union Chimique Belge. The company has evolved from a diversified chemical company into a focused biopharmaceutical leader with approximately 8,500 employees worldwide. UCB concentrates on patient solutions in neurology and immunology, with a strong portfolio of approved medicines including Keppra for epilepsy, Cimzia for inflammatory diseases, and Vimpat for seizure disorders.

View full company profile

Therapeutic Areas

NeurologyImmunologyEpilepsyParkinson's DiseaseMultiple SclerosisRheumatoid ArthritisPsoriasisInflammatory Diseases

Other Myasthenia Gravis Drugs

DrugCompanyPhase
NipocalimabJohnson & JohnsonPhase 3
IMVT-1402Roivant SciencesRegistrational
KYV-101Kyverna TherapeuticsPhase 1/2
Descartes-08Cartesian TherapeuticsPhase 2